Navigation Links
Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
Date:5/27/2008

LOS ANGELES, May 27 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today reported that CorCell Companies Inc., Philadelphia, Pa., which it acquired in October 2006, had its first operationally profitable quarter ever for the three months ending March 31, 2008.

CorCell, at the time of the purchase, was the fourth largest umbilical cord blood bank in the U.S. Established in 1995, CorCell collects umbilical cord blood stem cells from hospitals in all 50 states and internationally. CorCell is especially known for its strategic partnerships with health insurers throughout the country.

"When we acquired CorCell, it was losing $150,000 per month. With lots of re-engineering and hard work, the team has put the company in position to be highly successful. By streamlining CorCell's operations, we have turned it into a profitable entity," said Matthew Schissler, CEO, Cord Blood America. "We look for a continuation of this positive trend throughout 2008."

On May 20, 2008, the Company filed its Form 10-QSB with the United States Securities and Exchange Commission. In this document, it is noted that the Company posted an operational loss of $400,000. Mr. Schissler commented, "We have six subsidiaries under the parent Company. The operational loss came from losses of other business units, public Company expenses, and depreciation and amortization. Our operational loss decreased over 20% year over year. We're very excited for getting our largest business unit with the highest gross profits to achieve operational profitability first."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

CONTACT:

Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Iowa Resident Dies After Using Contaminated Blood Thinner
2. Global Blood Resources On-Line Calculator Reveals Wasted Blood Costs by Blood Salvage Machines During Heart Surgery to be in the Billions
3. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
4. Cord Blood America in Top 20 in Los Angeles Area Biotech-Biomed Companies
5. Cord Blood America Reports $5.8 Million In Revenues In 2007, Up 74 Percent
6. Stem Cells From Menstrual Blood Show Therapeutic Potential
7. Cord Blood America Says Pennsylvania Joins New York and California in Establishing Educational Programs on the Benefits of Umbilical Cord Blood Storage
8. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
9. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
10. Device That Clears Debris From Artery Aids Blood Flow in PCI
11. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):